World Patient Safety Day: A Call to Action When Safety Fails

Today , World Patient Safety Day, we must confront a harsh truth: systemic failures in medicine are not past history. They are ongoing. And when safety fails, it is innocent lives, pregnant women, children, families, who bear the lasting, often irreversible cost.

Over the past two days we have been honoured to attend the Health Service Journalโ€™s Patient Safety Congress , the UKโ€™s leading Patient Safety Forum. HSJ get it absolutely right. They bring together policymakers and professionals, but crucially they also give voice to those who have been harmed, bereaved, those using grief and trauma to demand change. The most amazing people who through tragedy, never wanted or expected to be in this realm of campaigning, but like us here , want real change and safety, because it matters and saves lives. HSJ provide a platform for ideas rooted in lived experience. Wouldnโ€™t it be something if these very people , those with the deepest insight into what goes wrong – were in charge of designing safety systems, instead of civil servants who too often treat safety as a checklist rather than a moral imperative?

As the leading voices and recognised Valproate Campaign, Emma was invited to speak on a panel at the Conference titled โ€œWhat Happens When Safety Fails?โ€ and chaired by Sunday Times Health Editor Shaun Lintern. She was joined on the panel by Kath Sanson (Sling the Mesh Campaign) Dr Sonia McCloud (Oxford University), Charlotte Harpin(Browne Jacobson) and Dr Shruthi Narayan (NHS Blood and Transfusion) We reflected on the Valproate scandal, mesh, and the routes of clinical negligence etc.


The Ongoing Price of Harm

We hear time and again that โ€œwe must learn the lessonsโ€. As campaigners it is something we hate hearing and often roll our eyes at. Reviews, inquiries, committees, action plans are all put in place. But the harm continues. Because learning alone is not enough without accountability, investment, and system-wide willingness to change.

A striking example of the cost , both human and financial , of patient safety failing:

  • In 2024โ€“25, the NHS paid ยฃ3.1 billion in clinical negligence compensation and legal costs (Clinical Services Journal).
  • The estimated annual cost of harm , the wider cost of incidents that should never happen , is ยฃ4.9 billion (Law Gazette).
  • Liabilities for future negligence claims now exceed ยฃ60 billion (Medscape).

These figures are not just numbers. They represent money diverted from safe staffing, from continuity of care, from services that protect women and babies.

Yet despite these astronomical figures, compensation for families affected by Valproate remains unresolved. Two Government-backed inquiries :

the IMMDS Report and, most importantly, the Hughes Report

recommend proper compensation and interim payments for children harmed by Valproate. These children and adults face lifelong barriers: loss of earnings, lack of opportunities, complex care needs, inaccessible housing, health costs, and the emotional toll on parents who must often give up work to provide full-time care.

Bureaucracy stands in the way. Just last week, we travelled to No.10 Downing Street with two disabled adults harmed by Valproate to hand-deliver a letter to the Prime Minister to highlight that 5 years since The Cumberlege Review, and 18 months since the Hughes report published, we are still waiting. for the recommendations to be meaningfully answered. The standard Government response, โ€œWe are working at pace and will respond soon,โ€ is simply not good enough. If patient safety truly mattered to those in power, they would act decisively instead of compounding trauma of already-harmed families.


Medical Misogyny: A Persistent Force

Across almost every major healthcare scandal reported in the media, a common thread emerges: medical misogyny – the systematic dismissal, minimisation, gaslighting or outright denial of womenโ€™s concerns. For decades, mothers who questioned the safety of medicines or raised alarms about unusual symptoms were told their worries were unfounded or reassured that โ€œthe benefits outweigh the risks.โ€ Their lived experience was rarely treated as credible evidence.

The Valproate scandal is one of the clearest examples. Warnings about the dangers of Sodium Valproate in pregnancy were available for years, yet regulators and policymakers delayed action. Women were left unprotected because their voices were not considered data worthy of response. Only through relentless, patient-led campaigning, powered by mothers and carers fighting for their children ,did the system finally begin to acknowledge and address the harm.

This pattern extends far beyond Valproate. The devastating maternity scandals in Shrewsbury, Telford, Nottingham, and elsewhere tell similar stories: women reporting unbearable pain, worrying symptoms, or a gut instinct that something was wrong were too often ignored, patronised, or blamed. Their intuition, sometimes their very lives , was sacrificed to a culture that privileged hierarchy, convenience, or denial over listening and acting with urgency.

Until womenโ€™s experiences and expertise are treated as indispensable to evidence-based care, patient safety will remain compromised. True reform means embedding respect for womenโ€™s voices at every level of the healthcare system , from consultation rooms and wards to research, regulation, and government policy.


Tick-Boxes vs. True, Patient-Centred Care

So much of what is done in patient safety becomes about compliance: ticking boxes, filling forms, and protecting the system before the patient. System safety first and patient safety second. That needs to change, and for every patient, every mother, every child.

We must demand:

  1. Proper funding for the NHS, so staff are not overstretched, so safety is not compromised because of understaffing.
  2. Genuine listening to patients and families, listening to their concerns, not just consultation, but co-design of safety systems.
  3. Transparency and accountability, when harm occurs, admitting failings, learning deeply, not superficially.
  4. Government that treats harm seriously: not with inertia or excuses, but urgent, systemic correction.
  5. Patient voice matters, systemic change comes from those with lived experience. Listen and act more


The Government Has to Step Up

For too long, the burden of blame is deflected onto front-line professionals: the midwives, the nurses, the obstetricians. Or worse, onto mothers. But the real people who need to be made accountable are the top executives of the Healthcare system, the regulators, and the people in charge of regulation (Government)

The Government must:

  • Prioritize safety funding – prevention, staffing, monitoring.
  • Ensure that regulation is proactive, not reactive.
  • Make those in power answer for harm that could have been avoided.
  • Move beyond symbolic action plans and tick-box culture to meaningful structural reform.

Duty of Candour and the Hillsborough Law: Truth as Prevention

A vital step forward is enforcing a strong Duty of Candour – a legal and professional requirement for organisations and staff to be open and honest when something goes wrong. Whilst at Patient Safety Congress, the Prime Minister announced the long-awaited Hillsborough Law, which will underpin candour with a statutory duty of full disclosure in major public safety incidents. This is hugely welcome here at INFACT and fully support it.

History shows why this matters. In 1973, Government officials were aware of the teragenocity of Valproate yet still decided to grant a full liscense, yet evidence was hidden, and pregnant women were not told. The documents we here at INFACT found at the National Archives prove this case. That deliberate concealment continued until official warnings were finally released only eight years ago. The Valproate Scandal is not an accident of science; it is a man-made national scandal, born of secrecy and denial. Had candour been a legal obligation, backed by real consequences, thousands of children could have been protected, and parents spared decades of pain. Embedding a genuine culture of truth-telling, supported by the Hillsborough Law, is essential if we are to prevent medical scandals from ever happening again.


The Yellow Card Scheme: Missed Warnings, Missed Chances

Another critical learning point discussed at the Congress and on Emma’s panel was the Yellow Card Scheme, the system for reporting suspected side effects of medicines to the MHRA. The Yellow card scheme was introduced in 1976 and still at present, reporting is voluntary for doctors, meaning we do not capture the full picture of medicine-related harm. For fourteen years we have called for Yellow Card reporting to be made mandatory, so that if a patient raises a concern with their GP, the doctor must report it.

In all that time there have been many scandals related to medicines and devicesThalidomide, Valproate, Contaminated Blood, DES Daughters, Mesh, Primodos (and these are the reported and acknowledged campaigns – there will be many more needing attention!)

Had concerns about Valproate and the other medical scandals been systematically logged and analysed through a robust, mandatory Yellow Card process, the dangers might have been identified far earlier. This pattern repeats elsewhere: at the start of our campaign, we urged that Valproate warnings must be compulsory. We were told by a senior MHRA official, โ€œThat will never happen.โ€ Instead, the Valproate Toolkit was introduced as optional guidance , and, unsurprisingly, women were not consistently warned. Only when the Pregnancy Prevention Programme made those warnings mandatory did things begin to change.

This is a clear example of why patient safety cannot be left to discretion or goodwill. Mandatory systems save lives; optional systems leave people exposed. When agencies resist evidence-based calls for reform, they risk condemning thousands to avoidable harm.


Children Harmed: A Living Reminder

Children harmed by Valproate, by faulty maternity care, or by medicines in pregnancy are living embodiments of what happens when safety fails. They are not statistics. They are our responsibility. Their voices and their existence demand change.

On this World Patient Safety Day, letโ€™s move past all the empty slogans and instead insist on real change. Letโ€™s build a health system that prioritises patients, listens deeply, acts decisively. Because safety is life. And when safety fails, lives are changed forever.

We would like to thank the whole team at HSJ Patient Safety Conference for their hard work in assembling such a fabulous conference

Supporting Families with PIP: How INFACT Helps Those Affected by Fetal Valproate Spectrum Disorder (FVSD)

At INFACT, our mission is simple but powerful: to stand alongside and support children, young people, adults, and families living with Fetal Valproate Spectrum Disorder (FVSD). As the UKโ€™s leading national charity for FVSD, we understand the daily challenges families face and the barriers they often encounter when accessing Personal Independence Payment (PIP) and other support.

Many parents and carers tell us that securing PIP for their child or adult family member with FVSD can be stressful and overwhelming. PIP is designed to help disabled people manage the extra challenges and costs of daily living. Yet families often struggle to communicate the full impact of FVSD, despite it being a government-recognised lifelong disability and recognised by the NHS England , MHRA and World Health Organization.

Why We Created PIP Support Resources

FVSD affects nearly every aspect of daily life. From learning, memory, and communication, to mobility, mental health, and independence. Individuals with FVSD often require ongoing supervision, prompting, and support to safely manage everyday tasks. Without financial assistance, families face additional costs for care, therapies, transport, and essential daily living needs.

To address this, INFACT has developed official supporting letters and factsheets for families to attach to their PIP applications. These resources clearly explain how FVSD meets PIP criteria and provide families with the authority and credibility of a national charity supporting FVSD.

How INFACT Supports Families

As the UKโ€™s leading charity for FVSD, INFACT has been at the forefront of raising awareness, campaigning for recognition, and working with government, healthcare professionals, and organisations such as the World Health Organization. Our support is practical as well as advocacy-driven:

  • We provide PIP guidance and supporting letters for families affected by FVSD.
  • We offer information on daily living support, therapies, and care options.
  • We connect families with a community of parents, carers, and individuals who truly understand the challenges of living with FVSD.

Ensuring Families Get the Support They Deserve

Our goal is to make sure families are not left navigating the benefits system alone. The INFACT PIP Support Pack helps families demonstrate the full impact of FVSD on mobility and daily living, giving them the best chance of securing the support they need.

We are here to ensure that every person affected by FVSD can access the care, resources, and financial assistance they require to live as safely and independently as possible.

Can I Use INFACTโ€™s PIP Support Resources if My Child Hasnโ€™t Been Diagnosed with FVSD?

Yes – and we strongly encourage you to do so.

At INFACT, we believe that any child exposed to sodium valproate during pregnancy should be considered at risk of Fetal Valproate Spectrum Disorder (FVSD), even if a formal diagnosis has not yet been made. This view is supported by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and by leading clinical guidance.

Many children affected by valproate exposure may show subtle or evolving symptoms, such as learning difficulties, developmental delays, or sensory sensitivities, which can make diagnosis challenging. A lack of formal diagnosis does not mean that a child does not experience the day-to-day difficulties that FVSD causes.

For the purposes of Personal Independence Payment (PIP):

  • The focus is on how your childโ€™s condition affects their daily living and mobility, not solely on the presence of a formal label.
  • Families can use our support letters and factsheets to clearly explain the impact of valproate exposure, highlighting practical examples of assistance, supervision, or adaptations that your child requires.
  • Including information from a recognised charity like INFACT adds credibility and supports your evidence, regardless of formal diagnosis.

In short: If your child was exposed to valproate in utero and experiences challenges in learning, mobility, personal care, or daily functioning, you should use our PIP support resources. They are designed to help you explain the real-life impact of FVSD and secure the support your child needs.

At INFACT, we continue to fight for recognition, justice, and support for families living with FVSD : because no family should have to face these challenges alone.